This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignees: Ucb Biopharma Sprl, Ucbbiopharma Srl. Active years: 2019-2022.
Location History:
- Stotfold, GB (2019)
- Slough, GB (2022)
Company Filing History:
Years Active: 2019-2022
Title: Jon Leigh Rundle: Innovator in Biomarker Research
Introduction
Jon Leigh Rundle is a notable inventor based in Stotfold, GB. He has made significant contributions to the field of biomarker research, particularly in relation to IL-17 mediated diseases. With a total of 2 patents to his name, Rundle's work is paving the way for advancements in therapeutic monitoring.
Latest Patents
Rundle's latest patents focus on the use of lipocalin 2 (LCN2) as a biomarker for IL-17 inhibitor therapy efficacy. The present invention provides the use of lipocalin 2 as a biomarker for IL-17 mediated diseases and for monitoring the response of a patient to anti-IL-17 therapy. This innovative approach has the potential to enhance treatment outcomes for patients suffering from these conditions.
Career Highlights
Throughout his career, Jon Leigh Rundle has worked with prominent companies in the biopharmaceutical sector, including UCB Biopharma Sprl and UCB Biopharma Srl. His expertise in biomarker research has positioned him as a valuable asset in the industry.
Collaborations
Rundle has collaborated with notable professionals in his field, including Adam Samuel Platt and Stephen Edward Rapecki. These collaborations have further enriched his research and contributed to the advancement of biomarker applications.
Conclusion
Jon Leigh Rundle's innovative work in biomarker research, particularly regarding IL-17 mediated diseases, showcases his commitment to improving patient care through scientific advancements. His contributions are significant in the ongoing quest for effective therapies.